Taken together, these data indicate that KRAS4A and KRAS4B are both required for optimal growth of KRAS mutant lung and pancreatic tumor cells in vitro and in immunodeficient mice, but the effects of Kras4A inhibition on tumor growth in the context of an intact immune system remain to be established. Here, KRAS is linked to pancreatic neoplasm.